Arcellx to Participate in Two Upcoming Investor Conferences
2024年5月8日 - 5:00AM
ビジネスワイヤ(英語)
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company
reimagining cell therapy through the development of innovative
immunotherapies for patients with cancer and other incurable
diseases, today announced that management will participate in two
upcoming investor conferences:
BofA Securities Health Care Conference 2024 (In Person)
Presentation: Tuesday, May 14 at 3:40 p.m. PT
TD Cowen 5th Annual Oncology Innovation Summit (Virtual)
Fireside Chat: Tuesday, May 28 at 1:00 p.m. PT
A live webcast of these discussions will be accessible from
Arcellx’s website at www.arcellx.com in the Investors section. A
replay of the webcasts will be archived and available for 30 days
following the event.
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company
reimagining cell therapy by engineering innovative immunotherapies
for patients with cancer and other incurable diseases. Arcellx
believes that cell therapies are one of the forward pillars of
medicine and Arcellx's mission is to advance humanity by developing
cell therapies that are safer, more effective, and more broadly
accessible. Arcellx's lead product candidate, anito-cel (formerly
CART-ddBCMA), is being developed for the treatment of relapsed or
refractory multiple myeloma (rrMM) in a Phase 2 pivotal trial.
Anito-cel has been granted Fast Track, Orphan Drug, and
Regenerative Medicine Advanced Therapy designations by the U.S.
Food and Drug Administration.
Arcellx is also developing its dosable and controllable CAR T
therapy, ARC-SparX, through two Phase 1 programs, ACLX-001 for rrMM
and ACLX-002 in relapsed or refractory acute myeloid leukemia and
high-risk myelodysplastic syndrome. For more information on
Arcellx, please visit www.arcellx.com. Follow Arcellx on X
(Twitter) at @arcellx and LinkedIn.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements in this press release that are not purely
historical are forward-looking statements, including Arcellx's
expectations regarding the timing and outcomes of clinical trials
for its product candidates and the potential impact of its product
candidates and platforms on patients and cell therapy. The
forward-looking statements contained herein are based upon
Arcellx's current expectations and involve assumptions that may
never materialize or may prove to be incorrect. These
forward-looking statements are neither promises nor guarantees and
are subject to a variety of risks and uncertainties, including
risks that may be found in the section entitled “Part I, Item 1A
(Risk Factors) in the Annual Report on Form 10-K for the fiscal
year ended December 31, 2023, filed with the Securities and
Exchange Commission (SEC) on February 28, 2024, and other documents
that Arcellx files from time to time with the SEC. These
forward-looking statements are made as of the date of this press
release, and Arcellx assumes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506085846/en/
Investors: Myesha Lacy ir@arcellx.com 510-418-2412
Media: Andrea Cohen Sam Brown Inc. andreacohen@sambrown.com
917-209-7163
Arcellx (NASDAQ:ACLX)
過去 株価チャート
から 10 2024 まで 11 2024
Arcellx (NASDAQ:ACLX)
過去 株価チャート
から 11 2023 まで 11 2024